Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study.

A, Pandit; N, Bhalani; BLS, Bhushan; P, Koradia; S, Gargiya; V, Bhomia; K, Kansagra

doi:10.1016/j.ijid.2021.03.015

Public

Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study.

Shared by NobleBlocks on Mar 10, 2021 • 12:00 AM UTC

Authors:

Pandit A

Bhalani N

Bhushan BLS

Abstract

<h4>Objective</h4>To evaluate the efficacy and safety of pegylated interferon alfa-2b (PEG IFN-α2b) along with the standard of care (SOC) in subjects with moderate COVID-19.<h4>Methods</h4>In this phase 2, randomized, open-label study, adult subjects aged ≥18 years with RT-PCR confirmed COVID-19 wit...

Subject

Antiviral

Coronavirus

Covid-19

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!